The Flow Cytometry Core provides USC Norris Comprehensive Cancer Center (NCCC) members access to advanced multi-parameter cellular analytic and cell sorting capabilities which includes the fluorescence activated cell sorting (FACS) of various populations of cells to provide a purified cell population for the researchers. The Core also provides expertise to allow investigators to analyze the expression of various markers on a cell population using fluorescence-based methods. This Core is administratively managed by the Broad Center for Regenerative Medicine and Stem Cell Research (CSCRM). Previously, flow cytometry services were provided by a core facility managed by NCCC with partial support from the CCSG. On December 1, 2009, NCCC partnered with CSCRM, who took over the provision of flow cytometry services to NCCC investigators under the directorship of Dr. Gregor Adams. This transition was a direct result of the NCCC Executive Committee's review of its shared resources in mid-2008, and endorsed by the NCCC's External Advisory Committee in April 2009. The partnership benefits NCCC investigators by giving them access to newer cytometers with more capabilities, as well as a reduction in the cost of flow cytometry services. The Core currently maintains four cytometers, a Beekman Coulter CyAn analyzer, a BD LSR II analyzer, BD FACSAria and BD FACSAria 11 cell sorters. The LSRII and the Aria are equipped with a 350 nm UV, a 488 nm argon laser, and a 635 nm red diode laser, while the Aria II is equipped with a 405 nm violet laser, a 488 nm argon laser and a 633 nm red diode laser, which will ultimately permit up to 15 parameter analysis.
Many cancer research projects require the isolation of a purified population of cells for analysis. The Flow Cytometry Core provides all of the necessary expertise and facilities to perform these experiments. This is an essential component of research aimed at treating many malignant conditions.
|Bensman, Timothy J; Jayne, Jordanna G; Sun, Meiling et al. (2017) Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. Antimicrob Agents Chemother 61:|
|Thomas, Duncan C (2017) Estimating the Effect of Targeted Screening Strategies: An Application to Colonoscopy and Colorectal Cancer. Epidemiology 28:470-478|
|Thomas, Duncan C (2017) What Does ""Precision Medicine"" Have to Say About Prevention? Epidemiology 28:479-483|
|Schwitzer, Emily; Orlow, Irene; Zabor, Emily C et al. (2017) No association between prediagnosis exercise and survival in patients with high-risk primary melanoma: A population-based study. Pigment Cell Melanoma Res 30:424-427|
|Okazaki, Satoshi; Stintzing, Sebastian; Sunakawa, Yu et al. (2017) Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer 141:1222-1230|
|Liang, Gangning; Weisenberger, Daniel J (2017) DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. Epigenetics 12:416-432|
|Kim, Yong-Mi; Gang, Eun-Ji; Kahn, Michael (2017) CBP/Catenin antagonists: Targeting LSCs' Achilles heel. Exp Hematol 52:1-11|
|Reid, Brett M; Permuth, Jennifer B; Chen, Y Ann et al. (2017) Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev 26:116-125|
|Poulard, Coralie; Bittencourt, Danielle; Wu, Dai-Ying et al. (2017) A post-translational modification switch controls coactivator function of histone methyltransferases G9a and GLP. EMBO Rep 18:1442-1459|
|Tokunaga, Ryuma; Zhang, Wu; Naseem, Madiha et al. (2017) CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev 63:40-47|
Showing the most recent 10 out of 739 publications